Chris Howerton
Stock Analyst at Jefferies
(2.69)
# 1,929
Out of 5,140 analysts
71
Total ratings
47.27%
Success rate
19.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $7.93 | -5.42% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $93.79 | +33.28% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $7.99 | +0.13% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.01 | +99.00% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.59 | +286.10% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.84 | +19,030.43% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $15.76 | +4,468.53% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.11 | -76.30% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $19.23 | -48.00% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $21.51 | -48.86% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $20.95 | +90.93% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $36.69 | +66.26% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $189.10 | -52.41% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.21 | +9,533.91% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $26.17 | +152.20% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.30 | +249.21% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.14 | +1,742.11% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.60 | +3,578.93% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $26.76 | -21.52% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $15.05 | +3,753.82% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.49 | +2,309.64% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $36.31 | -55.94% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $83.89 | -67.82% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $2.25 | +53,233.33% | 1 | May 26, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $7.93
Upside: -5.42%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $93.79
Upside: +33.28%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $7.99
Upside: +0.13%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.01
Upside: +99.00%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.59
Upside: +286.10%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.84
Upside: +19,030.43%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $15.76
Upside: +4,468.53%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.11
Upside: -76.30%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $19.23
Upside: -48.00%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $21.51
Upside: -48.86%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $20.95
Upside: +90.93%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $36.69
Upside: +66.26%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $189.10
Upside: -52.41%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.21
Upside: +9,533.91%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $26.17
Upside: +152.20%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $6.30
Upside: +249.21%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.14
Upside: +1,742.11%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.60
Upside: +3,578.93%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $26.76
Upside: -21.52%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $15.05
Upside: +3,753.82%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.49
Upside: +2,309.64%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $36.31
Upside: -55.94%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $83.89
Upside: -67.82%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $2.25
Upside: +53,233.33%